Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-742-4 | CAS number: 865-49-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian germ cell study: cytogenicity / chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- publication
- Title:
- Acute and subacute cytogenetic effects of the trihalomethanes on rat bone marrow cells in vivo
- Author:
- Fujie K, Aoki T and Wada M
- Year:
- 1 990
- Bibliographic source:
- Mutat Res 242, 111-119
Materials and methods
- GLP compliance:
- not specified
- Type of assay:
- other: Mammalian bone marrow chromosome aberration assy
Test material
- Reference substance name:
- Chloroform
- EC Number:
- 200-663-8
- EC Name:
- Chloroform
- Cas Number:
- 67-66-3
- Molecular formula:
- CHCl3
- IUPAC Name:
- chloroform
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Long-Evans
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Department of Pathology, Kobe University School of Medicine (Outbred from the colony of Ben May Laboratory for Cancer Research, University of Chicago)- Age at study initiation: 4 to 5 weeks- Weight at study initiation: 50 to 100 g- Housing: Commercial bedding (White Flakes, Charles River Japan Co.)- Diet (e.g. ad libitum): commercial solid food, Oriental Yeast Co., Tokyo- Water (e.g. ad libitum): ad libitum- Acclimation period:ENVIRONMENTAL CONDITIONS- Temperature (°C): 22 - Humidity (%): 60- Photoperiod (hrs dark / hrs light): natural light cycle
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- Physiological saline
- Details on exposure:
- 0.01, 0.1, and 1 mmol/kg bodyweight (1.2, 11.9, and 119.4 mg/kg) dissolved in physiological saline
- Duration of treatment / exposure:
- five consecutive days
- Frequency of treatment:
- daily administration
- Post exposure period:
- Sampling 18 hours after the last sampling (1.2, 11.9, and 119.4 mg/kg)6, 12, 18 and 24 hours after the last sampling (119.4 mg/kg)
Doses / concentrations
- Remarks:
- Doses / Concentrations:1.2, 11.9, and 119.4 mg/kgBasis:
- No. of animals per sex per dose:
- three
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- 1.5 mmol/kg (250.5 mg/kg) of potassium bromate (KBrO3)
Examinations
- Tissues and cell types examined:
- Metaphase cells in femoral bone marrow
- Details of tissue and slide preparation:
- Chromosome analysis: At various times after treatment with the chemicals, the animals were killed to study the frequency of aberrant metaphase cells in femoral bone marrow. The animals were injected with colchicine (0.3 mg dissolved in 0.3 ml of physiological saline) 1 h before death. Chromosome specimens were prepared from the femoral bone marrow by a conventional method, stained in 2% Giemsa solution (pH 6.8) for 15 min, and microscopically analyzed under code. Chromosome aberrations (CA) consisted of breaks and gaps: gaps were defined as complete interruptions in the continuity of one or both chromatids not exceeding the width of a chromatid, and breaks as discontinuities greater than the width of a chromatid, irrespective of whether or not the distal fragment was dislocated. Cells with gaps were not included in the category of damaged cells, based on the general opinion that gaps are not a good indicator of chromosome damage. About 100-200 metaphase cells were examined per rat, and the percentage of aberrant metaphase cells were calculated. Each group consisted of 3-6 rats.
- Evaluation criteria:
- Positive results were defined by significant differences revealed by the X2-test. A trend test was used for evidence of dose response.
- Statistics:
- Positive results were defined by significant differences revealed by the X2-test. A trend test was used for evidence of dose response.
Results and discussion
Test results
- Sex:
- male
- Genotoxicity:
- positive
- Toxicity:
- not specified
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Dose-response relationships were studied in cells sampled 18 h after the fifth and last day of treatment. Compared to the values for the untreated control, significant increases in CA were noted with 1 mmole CHCl3/kg (119.4 mg/kg). The percent of aberrant metaphase cells over time was determined 6, 12, 18, and 24 h after the fifth and last day of oral treatment at1 mmole CHCl3/kg (119.4 mg/kg) Compared to the values for the untreated control, significant increases in CA were noted at 24h x5+12h,and 24hX5+18h with CHCl3. The incidence of aberrant cells increased gradually, and reached the maximum level at 18 h after the last treatment, decreasing to the control level at 24 h after the last treatment.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): positiveThe kinetic of the chromosomal aberrations at 1 mmol/kg is not traditional: positive 12 and 18 hours after five daily administration and negative 6 and 24 hours after the same treatment. Such a kinetic is not compatible with the kinetic of specific chromosomal aberrations but more with a cytotoxic activity. Unfortunately, no information about the cytotoxic activity in the bone marrow is available.In addition, considering the toxicokinetic data available in rats after oral or i.p. administrations of chlororoform (e.g. Wang et al., 1995)(1) , it is not plausible that the very low tissue levels of chloroform resulting from an oral or i.p. dose of 1.2 mg/kg/ could be at the origin of a clastogenic activity. Such positive results should then be considered as equivocal.(1): for example, Wang et al (1995) found that chloroform blood concentrations are around 0.1 mM (12 µg/mL) 60 minutes after an oral administration of 100 mg/kg. Wang P-Y, Kaneko T, Sato A, Charboneau M & Plaa GL (1995) Dose- and route-dependant alteration of metabolism and toxicity of chloroform in fed and fasting rats. Toxicol. appl. Pharmacol., 135, 119-126.
- Executive summary:
In a chromosomal aberration assay, groups of 3 male Long-Evans rats were treated orally (gavage) with chloroform (dissolved in redistilled water and physiological saline) at doses of 1.2, 11.9, and 119.4 mg/kg bodyweight once daily for five consecutive days.
One group of 3 males, acting as control group, received the vehicle (physiological saline solution) and another group of 3 males received the positive control test item (potassium bromate) at the dose-level of 250.5 mg/kg, under the same experimental conditions than the chloroform treated groups.
The animals were killed 18 hours after receiving the last dose to study the frequency of aberrant metaphase cells in femoral bone marrow cells. Compared to control group, a dose-related increase in the incidence of aberrant cells and of the number of aberration per cell was observed. This difference was statistically significant at the high dose (6% versus 1% for the controls). Various times of sampling (6, 12, 18 and 24 hours after the last dosing) were also performed at the high dose and indicated that the incidence of aberrant cells increased gradually to reach a maximum level 18 hours after the last treatment. No more increase was observed 24 hours after the last treatment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.